The Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia

NANot yet recruitingINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

August 31, 2027

Conditions
FibromyalgiaPregabalinPain
Interventions
DRUG

Pregabalin

In the pregabalin monotherapy group, pregabalin will be initiated at 150 mg daily, divided into 2 or 3 doses per day, and increased to 300 mg per day after 3 to 7 days, subsequent increases of 150 mg daily may occur every 3 to 7 days, based on individual patient response and tolerability, with a maximum dose of 600 mg daily.

DRUG

Pregabalin with desvenlafaxine

In the pregabalin with desvenlafaxine group, the dose titration of pregabalin is identical with pregabalin monotherapy group. Desvenlafaxine will be administered at 50 mg daily with breakfast initially. If the initial dose is well-tolerated, the dose could be further escalated by 50 mg per day after 3 days, up to a maximum of 400 mg per day after 7 days. With each dose increase, AEs will be assessed and categorized as mild, moderate, or severe. If participants tolerate the current dose for 2 to 3 days, it will be maintained, with the expectation that tolerance to AEs will develop. If AEs become intolerable, the dose will be decreased back to the previous dose, which was defined as the maximum tolerated dose. In the combination group, dose titration of both pregabalin and desvenlafaxine will be conducted simultaneously. If AEs occur, the next dose regimen should be determined in consultation with a clinical physician.

Trial Locations (1)

Unknown

Beijing Tiantan Hospital, Beijing, Beijing 100070, Beijing

All Listed Sponsors
collaborator

Jiujiang University Affiliated Hospital

OTHER_GOV

lead

Beijing Tiantan Hospital

OTHER